Nasdaq · CIK 0001776111
MBX MBX Biosciences, Inc.
Insider trading from SEC Form 4. Last filing Feb 3, 2026. Close $53.24 on Oct 9, 2026, +303% from the 52-week low and -25% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Price and insider trades, last year
MBXOct 9, 2026 · close 53.24
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at MBX Biosciences, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | P. Kent Hawryluk President & CEO buy | $273k 20,000 shares | +4% | +146% from low-41% from high | |
| 52Moderate | Steven L. Hoerter director buy | $265k 20,000 shares | - | +128% from low-45% from high | |
| 51Moderate | Patrick J Heron director, owner buy | $12M 666,666 shares | +15% | +202% from low-33% from high | |
| 45Moderate | Ora H. Pescovitz director buy | $45k 7,693 shares | +46% | 0% from low-78% from high | |
| 51Moderate | Carl L Gordon director, owner buy | $2.0M 190,672 shares | +6% | - | |
| 54Moderate | P. Kent Hawryluk President & CEO buy | $535k 50,000 shares | +13% | - |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Richard Bartram Chief Financial Officer | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 15,000 | Feb 3, 2026 |
| Feb 2, 2026 | Salomon Azoulay Chief Medical Officer | AGrant or award Common Stock | +15,000 | $0.00 | $0 | 15,000 | Feb 3, 2026 |
| Feb 2, 2026 | Salomon Azoulay Chief Medical Officer | AGrant or award Stock option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Feb 3, 2026 |
| Feb 2, 2026 | Richard Bartram Chief Financial Officer | AGrant or award Stock option (right to buy)derivative | +70,000 | $0.00 | $0 | 70,000 | Feb 3, 2026 |
| Nov 22, 2025 | Steven L. Hoerter director | AGrant or award Stock option (right to buy)derivative | +8,000 | $0.00 | $0 | 8,000 | Nov 25, 2025 |
| Nov 6, 2025 | Steven L. Hoerter director | AGrant or award Stock option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Nov 7, 2025 |
| Oct 24, 2025 | P. Kent Hawryluk President & CEO | MOption exercise Common Stock | +182,859 | $3.25 | $594k | 664,256 | Oct 28, 2025 |
| Oct 24, 2025 | P. Kent Hawryluk President & CEO | MOption exercise Stock option (right to buy)derivative | -182,859 | $0.00 | $0 | 129,708 | Oct 28, 2025 |
| Oct 20, 2025 | P. Kent Hawryluk President & CEO | POpen-market purchase Common Stockindirect: By Trust | +20,000 | $13.64 | $273k | 468,277 | Oct 21, 2025 |
| Oct 17, 2025 | Steven L. Hoerter director | POpen-market purchase Common Stockindirect: By Trust | +20,000 | $13.25 | $265k | 20,000 | Oct 20, 2025 |
| Sep 26, 2025 | Patrick J Heron director, owner | POpen-market purchase Common Stockindirect: By Frazier Life Sciences X, L.P. | +666,666 | $18.00 | $12M | 5,219,440 | Sep 30, 2025 |
| Jun 5, 2025 | Steven L. Hoerter director | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | Edward T Mathers director, owner | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | Steven Ryder director | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | Ora H. Pescovitz director | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | Patrick J Heron director, owner | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | James M Cornelius director | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Jun 5, 2025 | Tiba Aynechi director | AGrant or award Stock option (right to buy)derivative | +16,000 | $0.00 | $0 | 16,000 | Jun 6, 2025 |
| Apr 8, 2025 | Ora H. Pescovitz director | POpen-market purchase Common Stock | +7,693 | $5.89 | $45k | 24,329 | Apr 10, 2025 |
| Apr 7, 2025 | Steven L. Hoerter director | AGrant or award Stock option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 9, 2025 |
| Feb 14, 2025 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +17,962 | $9.90 | $178k | 3,176,390 | Feb 19, 2025 |
| Feb 14, 2025 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +29,540 | $9.85 | $291k | 3,205,930 | Feb 19, 2025 |
| Feb 18, 2025 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +49,070 | $10.84 | $532k | 3,255,000 | Feb 19, 2025 |
| Feb 18, 2025 | Carl L Gordon director, owner | POpen-market purchase Common Stockindirect: See footnotes | +94,100 | $10.84 | $1.0M | 747,887 | Feb 19, 2025 |
| Feb 4, 2025 | P. Kent Hawryluk President & CEO | POpen-market purchase Common Stockindirect: By Trust | +50,000 | $10.69 | $535k | 448,277 | Feb 5, 2025 |
| Feb 3, 2025 | Salomon Azoulay Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Feb 5, 2025 |
| Feb 3, 2025 | Richard Bartram Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +95,000 | $0.00 | $0 | 95,000 | Feb 5, 2025 |
| Feb 3, 2025 | P. Kent Hawryluk President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +243,000 | $0.00 | $0 | 243,000 | Feb 5, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Tiba Aynechidirector
- Salomon AzoulayChief Medical Officer
- Richard BartramChief Financial Officer
- James M Corneliusdirector
- Carl L Gordondirector, owner
- P. Kent HawrylukPresident & CEO
- Patrick J Herondirector, owner
- Steven L. Hoerterdirector
- Edward T Mathersdirector, owner
- Ora H. Pescovitzdirector
- Steven Ryderdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.